Athersys (NASDAQ:ATHX) received a $6.00 price target from Maxim Group in a note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target would indicate a potential upside of 325.53% from the stock’s previous close.
Separately, ValuEngine raised shares of Athersys from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd.
Shares of Athersys (NASDAQ ATHX) opened at $1.41 on Tuesday. Athersys has a one year low of $1.08 and a one year high of $2.63.
Large investors have recently bought and sold shares of the stock. Royal Bank of Canada boosted its position in shares of Athersys by 7,334.0% during the 2nd quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 375,723 shares during the period. Perkins Capital Management Inc. purchased a new position in shares of Athersys during the 3rd quarter worth approximately $636,000. Bank of New York Mellon Corp boosted its position in shares of Athersys by 11.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 318,038 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 33,498 shares during the period. Vanguard Group Inc. boosted its position in shares of Athersys by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock worth $6,441,000 after purchasing an additional 366,572 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Athersys by 30.8% during the 2nd quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock worth $1,697,000 after purchasing an additional 264,549 shares during the period. 20.20% of the stock is owned by hedge funds and other institutional investors.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.